Preservative-Free Tiotropium Nebulization Solution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current inhalation solutions for COPD treatment, such as those containing tiotropium, often include preservatives like benzalkonium chloride, which can cause adverse effects like paradoxic bronchoconstriction and occupational asthma, and require complex dosing and administration procedures, leading to potential treatment failures and increased costs.
Innovation Solution
A sterile, preservative-free and complexing agent-free tiotropium solution for inhalation via nebulization, formulated without benzalkonium chloride or EDTA, providing a stable and easy-to-administer option for COPD treatment, available in prepackaged, premeasured units for direct use with a nebulizer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If preservatives like benzalkonium chloride are added to inhalation solutions, then the solution stability is improved, but adverse effects such as paradoxic bronchoconstriction and occupational asthma increase
Solution Approach 1:
The patent removes preservatives like benzalkonium chloride from the inhalation solution formulation. By extracting the harmful preservative component while maintaining the active pharmaceutical ingredient (tiotropium) in a sterile, preservative-free formulation, the solution achieves stability through alternative means (sterile filtration, proper packaging) without exposing patients to harmful substances that cause bronchoconstriction and occupational asthma.
Solution Approach 2:
The patent changes the formulation parameters by eliminating preservatives and complexing agents, creating a simplified solution with tiotropium as the primary active ingredient. This parameter change from complex multi-component formulations to streamlined preservative-free formulations resolves the contradiction by achieving stability through sterile manufacturing and packaging rather than chemical preservatives.
2Reliability
If complex dosing and administration procedures are used, then treatment coverage is improved, but treatment failure risk and costs increase
Solution Approach 1:
The patent divides the treatment into simple, discrete unit doses where each inhalation solution contains a pre-determined, optimal amount of tiotropium. This segmentation into standardized units eliminates the need for complex dosing calculations and mixing procedures, while ensuring each dose provides adequate treatment coverage. The simple act of inhaling the nebulized solution delivers the full therapeutic effect without requiring complex administration protocols.
Data Source
AI summary
The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.